$BLSM SEC Filings

Filed On	Filing
18 Sep 2026	8-K: Results of Operations and Financial Condition Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering
18 Sep 2026	10-Q
15 Sep 2026	8-K: Regulation FD Disclosure 45% objective response rate and 88% disease control rate observed in patients with
18 Aug 2026	SCHEDULE 13D
17 Aug 2026	SCHEDULE 13G
14 Aug 2026	SCHEDULE 13G
13 Aug 2026	SCHEDULE 13D
12 Aug 2026	Form 4: Gordon Carl L, Director Received 2,089,279 shares by conversion · Bought 625,000 shares ($10M)
12 Aug 2026	Form 4: Orbimed Advisors Llc, Director and 1 other Received 2,089,279 shares by conversion · Bought 625,000 shares ($10M)
10 Aug 2026	Form 4: Gordon Carl L, Director Granted 23,904 Director Stock Option (Right to Buy)
10 Aug 2026	Form 4: Chen Bihua, Director and 5 others Granted 23,904 Director Stock Option (Right to Buy) · Received 3,301,534 shares by conversion · Bought 312,500 shares ($5M)
10 Aug 2026	Form 4: Schmid John P., Director Bought 6,000 shares ($96K)
10 Aug 2026	Form 4: Keyes Jason A, Chief Financial Officer Granted 56,746 Employee Stock Option (Right to Buy) · Bought 700 shares ($11.2K)
10 Aug 2026	Form 4: Liptak Vincent Paul, General Counsel Granted 46,561 Employee Stock Option (Right to Buy) · Bought 2,500 shares ($39.5K) · Bought 2,200 shares ($35.2K) · 1 more
10 Aug 2026	Form 4: Oxnard Geoffrey Raymond, Chief Medical Officer Granted 61,783 Employee Stock Option (Right to Buy)
10 Aug 2026	Form 4: Agrawal Sundeep, Director Granted 23,904 Director Stock Option (Right to Buy) · Received 578,524 shares by conversion
10 Aug 2026	Form 4: Li Yishan, Director Granted 112,701 Employee Stock Option (Right to Buy) · Received 1,838,896 shares by conversion
10 Aug 2026	Form 4: Cui Jingrong Jean, Director Granted 676,205 Employee Stock Option (Right to Buy) · Received 1,838,896 shares by conversion
10 Aug 2026	S-8
10 Aug 2026	8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events

Comments